Clinical Trial Update: An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders [Phase 2]

View source ↗

Summary

An open-label Phase 2 study of aripiprazole in autism spectrum disorders has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asperger Disorder
• Autism Spectrum Disorder
• Pervasive Developmental Disorder

Drugs mentioned

• Abilify (aripiprazole)

Snippet

Sponsor: Cambridge Health Alliance | Conditions: Autism, Asperger's Disorder | Phase 2 | Status: COMPLETED | Results posted: 2017-01-02